Iovance Biotherapeutics (IOVA) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Iovance Biotherapeutics (IOVA) has outperformed Vericel (VCEL) over the past year, gaining 208.0% versus a gain of 45.3%. Over five years, VCEL leads with a +50.1% price change compared with -62.7% for IOVA. Iovance Biotherapeutics is the larger company by market cap ($3.19 billion vs $2.94 billion), about 1.1 times the size.
Vericel converts more of its revenue into profit, with a net margin of 6.0% versus -148.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IOVA | VCEL |
|---|---|---|
| Share price | $6.90 | $57.52 |
| Market cap | $3.19B | $2.94B |
| 1-day change | -5.61% | -1.27% |
| YTD return | +152.75% | +59.73% |
| 1-year return | +208.04% | +45.33% |
| 5-year return | -62.70% | +50.14% |
| P/E ratio (TTM) | — | 89.88 |
| Forward P/E | — | 61.06 |
| EPS (TTM) | $-0.49 | $0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $263.50M | $276.26M |
| Revenue growth (YoY) | +60.60% | +16.45% |
| Net income (latest FY) | $-390.98M | $16.52M |
| Gross margin | 34.28% | 74.42% |
| Operating margin | -153.08% | 4.00% |
| Net margin | -148.38% | 5.98% |
| 52-week high | $15.37 | $59.75 |
| 52-week low | $2.08 | $28.95 |
| Distance from 52-week high | -55.11% | -3.73% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +110.14% | +13.75% |
| Average volume | 14.91M | 664.34K |
| Shares outstanding | 462.66M | 51.03M |
| Employees | 975 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IOVA has outperformed VCEL by 162.7 percentage points over the past year.
- Vericel is more profitable, keeping 6.0 cents of every revenue dollar as net income versus -148.4 cents for Iovance Biotherapeutics.
- Iovance Biotherapeutics grew revenue faster in its latest fiscal year (+60.60% vs +16.45%).
About Iovance Biotherapeutics
IOVA stock →Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 975 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
IOVA vs VCEL FAQ
Which is bigger, Iovance Biotherapeutics or Vericel?
Iovance Biotherapeutics (IOVA) is larger, with a market capitalization of $3.19B compared with $2.94B for Vericel (VCEL).
Which stock has performed better over the past year, IOVA or VCEL?
IOVA returned +208.04% over the past 12 months, compared with +45.33% for VCEL (price return, excluding dividends). Past performance does not predict future results.
Are Iovance Biotherapeutics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.